TABLE 1.
Baseline characteristics compared between patients with and without prolonged venous transit.
| Variable | Overall, N = 104 | PVT– group | PVT+ group | p a |
|---|---|---|---|---|
| N = 74 | N = 30 | |||
| Age, median (IQR), years | 70 (62, 79) | 70 (61, 78) | 72 (63, 82) | 0.42 |
| Sex, n (%) | ||||
| Female | 58 (56) | 45 (61) | 13 (43) | 0.1 |
| Male | 46 (44) | 29 (39) | 17 (57) | |
| Occlusion segment, n (%) | ||||
| ICA | 8 (7.7) | 4 (5.4) | 4 (13) | 0.38 |
| M1 | 76 (73) | 56 (76) | 20 (67) | |
| Poximal‐M2 | 20 (19) | 14 (19) | 6 (20) | |
| Smoking status, n (%) | 54 (52) | 36 (49) | 18 (60) | 0.32 |
| Alcohol use, n (%) | 32 (31) | 26 (36) | 6 (20) | 0.12 |
| Hypertension, n (%) | 83 (80) | 56 (76) | 27 (90) | 0.1 |
| Dyslipidemia, n (%) | 55 (53) | 39 (53) | 16 (53) | 0.95 |
| Diabetes, n (%) | 29 (28) | 19 (26) | 10 (33) | 0.43 |
| Heart disease, n (%) | 52 (50) | 38 (51) | 14 (47) | 0.67 |
| Atrial fibrillation, n (%) | 44 (42) | 33 (45) | 11 (37) | 0.46 |
| History of stroke/TIA, n (%) | 17 (16) | 12 (16) | 5 (17) | >0.99 |
| Chronic kidney disease, n (%) | 20 (19) | 15 (20) | 5 (17) | 0.67 |
| Sleep apnea, n (%) | 11 (11) | 8 (11) | 3 (10) | >0.99 |
| Admission NIHSS score, median (IQR) | 15 (11, 20) | 14 (10, 19) | 16 (14, 20) | 0.038 |
| Premorbid mRS score, n (%) | ||||
| 0 | 83 (81) | 57 (78) | 26 (87) | 0.32 |
| 1 | 20 (19) | 16 (22) | 4 (13) | |
| Stroke etiology (TOAST criteria), n (%) | ||||
| Large artery atherosclerosis | 14 (14) | 12 (16) | 2 (6.7) | 0.54 |
| Cardioembolism | 60 (58) | 40 (55) | 20 (67) | |
| Stroke of other determined etiology | 3 (2.9) | 2 (2.7) | 1 (3.3) | |
| Stroke of undetermined etiology | 26 (25) | 19 (26) | 7 (23) | |
| Occlusion laterality, n (%) | ||||
| Left | 45 (50) | 31 (47) | 14 (58) | 0.34 |
| Right | 45 (50) | 35 (53) | 10 (42) | |
Abbreviations: ICA, internal carotid artery; IQR, interquartile range; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; PVT, prolonged venous transit; TIA, transient ischemic attack; TOAST, Trial of ORG 10172 in Acute Stroke Treatment.
a
Wilcoxon rank sum test; Pearson's Chi‐squared test; Fisher's exact test.